INCY vs. TMO: Incyte vs. Thermo Fisher Scientific Stock Comparison
How do Incyte (INCY) and Thermo Fisher Scientific (TMO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Incyte (INCY) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.
| Profile Item | INCY | TMO |
|---|---|---|
| Name | Incyte Corp. | Thermo Fisher Scientific Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 24.39 billion USD | 257.42 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | November 4, 1993 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INCY | TMO |
|---|---|---|
| Total Return (1Y) | 14.06% | 24.62% |
| Total Return (3Y, Annualized) | 32.03% | 17.34% |
| Total Return (5Y, Annualized) | 12.69% | 3.11% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INCY | TMO |
|---|---|---|
| Volatility (1Y, Annualized) | 33.19% | 29.96% |
| Beta (5Y) | 0.78 | 0.83 |
| Max Drawdown (5Y) | -40.50% | -40.95% |
| Avg. Volume (3M) | 1.58M | 2.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INCY | TMO |
|---|---|---|
| Sharpe Ratio (1Y) | 0.29 | 0.68 |
| Sortino Ratio (1Y) | 0.46 | 1.02 |
Profitability
ROE (TTM)
Both Incyte (INCY) at 7.84% and Thermo Fisher Scientific (TMO) at 13.38% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.38%
- Max
- 109.18%
- TMO
- 13.38%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Incyte (INCY) at 6.71% and Thermo Fisher Scientific (TMO) at 14.94% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.94%
- Max
- 18.05%
- TMO
- 14.94%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Incyte (INCY) at 33.72% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.19%
- Max
- 83.12%
- TMO
- 20.19%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | INCY | TMO |
|---|---|---|
| ROE (TTM) | 7.84% | 13.38% |
| ROA (TTM) | 17.78% | 5.19% |
| Net Margin (TTM) | 6.71% | 14.94% |
| Operating Margin (TTM) | 33.72% | 20.19% |
| Gross Margin (TTM) | 56.02% | 41.26% |
Growth
Revenue Growth
Both Incyte (INCY) at 21.22% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Thermo Fisher Scientific (TMO) at 7.32%, which is closer to a typical peer reading.
Growth Metrics
| Metric | INCY | TMO |
|---|---|---|
| Revenue Growth (YoY) | 21.22% | 3.91% |
| Revenue Growth (3Y CAGR) | 14.84% | -0.27% |
| EPS Growth (YoY) | 4,173.33% | 7.32% |
| EPS Growth (3Y CAGR) | 61.56% | 0.21% |
Financial Strength
Current Ratio (MRQ)
Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Thermo Fisher Scientific (TMO) at 1.81 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TMO.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TMO
- 1.81
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Thermo Fisher Scientific (TMO) at 0.75 sits in the higher-leverage quartile.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.75
- Max
- 1.42
- TMO
- 0.75
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INCY | TMO |
|---|---|---|
| Current Ratio (MRQ) | 3.84 | 1.81 |
| Debt / Equity (MRQ) | 0.01 | 0.75 |
| Net Debt / EBITDA | -1.88 | 2.91 |
Dividends
Dividend Yield (TTM)
Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27%
- TMO
- 0.27%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.70%
- TMO
- 9.70%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INCY | TMO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.27% |
| Dividend Payout Ratio (TTM) | 0.00% | 9.70% |
Valuation
P/E Ratio (TTM)
Thermo Fisher Scientific (TMO) at 36.64 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.64
- Max
- 85.34
- Q3
- 43.46
- TMO
- 36.64
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Incyte (INCY) at 4.06 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- TMO
- 5.44
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Incyte (INCY) at 4.33 and Thermo Fisher Scientific (TMO) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- TMO
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INCY | TMO |
|---|---|---|
| P/E Ratio (TTM) | 61.05 | 36.64 |
| P/S Ratio (TTM) | 4.06 | 5.44 |
| P/B Ratio (MRQ) | 4.33 | 4.70 |
| Free Cash Flow Yield (TTM) | 5.28% | 2.50% |